HER-2/neu as a predictive marker of response to breast cancer therapy

Breast Cancer Research and Treatment

Volumn 52, Issue 1-3, 1998, Pages 65-77

  Pegram, Mark D ^a,b   Pauletti, Giovanni ^a   Slamon, Dennis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

c erbB 2; Chemotherapy; Drug resistance; HER 2 neu; Tamoxifen

Indexed keywords

ANTIESTROGEN; GROWTH FACTOR RECEPTOR; MARKER; REAGENT;

BREAST CANCER; CANCER STAGING; FEMALE; FOLLOW UP; GENE AMPLIFICATION; HUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; RECEPTOR, ERBB-2; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0032445260     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006111117877     Document Type: Review

References (39)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press M: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
3. Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944-948, 1991
4. Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, Gullick WJ, Elston CW, Blamey RW: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63:439-443, 1991
5. Berns PMJJ, Klijn JGM, van Staveren IL, Portengen H, Foekens JA: Prevalence of amplification of the oncogenes c-myc, HER-2/neu and int-2 in one thousand human breast tumors: correlation with steroid receptors. Eur J Cancer 28:697-700, 1992
6. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11:1936-1942, 1993
7. Toikkanen S, Helin H, Isola J, Joensuu H: Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10:1044-1048, 1992
8. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112, 1990
9. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D, for the Toronto Breast Cancer Study Group: neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 16:1340-1349, 1998
10. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire W: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
11. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville A, Burki K, Castiglione M, Collins J, Lindtner J, Senn H-J, for the International (Ludwig) Breast Cancer Study Group: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992
12. Levine MN, Andrulis I: The HER-2/neu oncogene in breast cancer: so what is new? [editorial; comment]. J Clin Oncol 10:1034-1036, 1992
13. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S: c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702-2708, 1996
14. Tetu B, Brisson J: Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immuno-staining and adjuvant therapy. Cancer 73:2359-2365, 1994
15. Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY, Portengen H, Klijn JG: Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159:11-18, 1995
16. Wright C, Cairns J, Cantwell BJ, Cattan AR, Hall AG, Harris AL, Horne CH: Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. Br J Cancer 65:271-274, 1992
17. Stender MJ, Neuberg D, Wood W, Sledge G: Correlation of circulating c-erbB-2 extracellular domain (Her-2) with clinical outcome in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 16: 154a, 1997
18. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson C: c-erbB-2 expression and response to adjuvant therapy in women with nodepositive early breast cancer. N Engl J Medicine 330:1260-1266, 1994
19. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-547, 1997
20. Stein D, Wu J, Fuqua SA, Roonprapunt C, Yajnik V, D'Eustachio P, Moskow JJ, Buchberg AM, Osborne CK, Margolis B: The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J 13:1331-1340, 1994
21. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL: Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 8:933-938, 1993
22. Nicholson S, Wright C, Sainsbury JR, Halcrow P, Kelly P, Angus B, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J Steroid Biochem Molec Biol 37:811-814, 1990
23. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, Harris AL, Horne CH: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992
24. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S, Sigurdsson H: ERBB2 amplification is associated with tamoxifen resistance in steroidreceptor positive breast cancer. Cancer Lett 81:137-144, 1994
25. Bianco AR, De Laurentiis M, Carlomagno C, Lauria R, Petrella G, Panico L, Pettinato G, Perrone F, Gallo C, Marinelli A, De Placido S: 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erbB-2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol 17: 373, 1998
26. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462-469, 1998
27. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446, 1995
28. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hosch S, Hayes DF: Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15:2518-2525, 1997
29. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135, 1995
30. HER2/neu monoclonal antibody (rhuMAb HER2) plus cisplatin in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol, 1998 (in press)
31. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95, 1993
32. HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263, 1993
33. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
34. Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Baselga J, Norton L: Addition of Herceptin (humanized anti-HER-2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multi-national controlled Phase III trial. Proc Am Soc Clin Oncol 17:377, 1998
35. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Paton V, Shak S, Lieberman G, Slamon D: Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 17:376, 1998
36. Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72, 1996
37. Graber JH, O'Donnell MI, Smith CL, Cantor CR: Advances in DNA diagnostics. Curr Opin Biotech 9:14-18, 1998
38. Neubauer A, Neubauer B, He M, Effert P, Iglehart D, Frye R, Liu E: Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene 7:1019-1025, 1992
39. Press MF, Hung G, Godolphin W, Slamon DJ: Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohisto-chemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994